Single-center retrospective analysis of maribavir in the treatment of refractory and drug-intolerant cytomegalovirus viremia and cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation (ASH 2025) - Nov 4, 2025 - Abstract #abs25-13023; 6059; Pres time: Dec 8, 2025; 06:00 PM - 08:00 PM; Location: OCCC - West Halls B3-B4; P3 | "Maribavir, a novel anti-CMV agent, exhibits multimodal anti-CMV activity without cross-resistance to ganciclovir or foscarnet...Fifty patients received letermovir for CMV prophylaxis...The 1-year overall survival rate was 86.5% (95% CI: 74.7%–98.4%). Conclusion Maribavir demonstrated high efficacy and a favorable safety profile in treating refractory or drug-intolerant CMV viremia and CMV disease post- allo HSCT, characterized by rapid viral clearance (shortmedian time to response) and minimal adverse effects."
Retrospective data • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Chronic Myeloid Leukemia • Cutaneous T-cell Lymphoma • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Lymphoblastic Lymphoma • Lymphoma • Multiple Myeloma • Myelodysplastic Syndrome • Nephrology • Pneumonia • Respiratory Diseases • Septic Shock • T Cell Non-Hodgkin Lymphoma • Transplantation
|
|
Wei Ma1; Xingyu Cao2; Jiarui Zhou3; Jian-Ping Zhang3; Yue Lu3; Ruijuan Sun1; Zhijie Wei1; Deyan Liu1; Yanli Zhao1; Min Xiong1; Peihua Lu1
|